Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | PKM | P14618 | 3/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245092 | 0.86 | GAA (1.00) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL4491035 | 0.83 | GAA (0.79) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL7006640 | 0.83 | GAA (0.79) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL318557 | 0.81 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL22281652 | 0.81 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL1185012 | 0.81 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL30071250 | 0.81 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL8285860 | 0.81 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL12426307 | 0.81 | GAA (0.82) | GAANPC1RAB9APKMHDAC3 | |
| SCHEMBL30440440 | 0.81 | GAA (0.76) | GAANPC1RAB9APKMHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022258007-A1 | SALT AND CRYSTAL FORM OF PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| CN-102908624-A | Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist | ASTRAZENECA SWEDEN AB | 2013-02-06 | — | — | CN | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| CN-102088976-B | Comprising a muscarinic receptor antagonist and beta2-pharmaceutical products of adrenoreceptor agonists | ASTRAZENECA AB | 2012-12-26 | — | — | CN | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1320529-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
| EP-1551829-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004035569-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-04-29 | — | — | WO | disclosed |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1373247-A2 | SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1320529-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002079189-A2 | SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002024684-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053928-A1 | Quinoline derivatives as antibacterials | AAAS, QDPR, QARS1 | GAA 2224/4885NPC1 3236/4885RAB9A 581/4885 |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | GAA 807/4885NPC1 959/4885RAB9A 529/4885 |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | GAA 3263/4885NPC1 566/4885RAB9A 1884/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | GAA 1902/4885NPC1 2038/4885RAB9A 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.